Corporation, a biopharmaceutical company specializing in proprietary therapeutics with a market capitalization of $14 billion ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to ...

Regeneron promotes EYLEA, Libtayo, and Dupixent at JPMorgan event while touting a pipeline that targets major disease areas.

(ImaginAb) to acquire a pipeline of next-generation therapeutic candidates, proprietary novel biologics technology platform ... These next generation drug candidates fit synergistically with Telix’s ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Amgen (AMGN – Research Report), retaining the price target of $362.00.Stay ...

In a report released yesterday, Justin Zelin from BTIG maintained a Buy rating on Immunocore Holdings (IMCR – Research Report), with a price ...

MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- (ASX: TLX, Nasdaq: TLX, Telix, the Company) today ...

(ImaginAb) to acquire a pipeline of next-generation therapeutic candidates ... enabling expansion to future therapy areas with unmet clinical need. The acquired intellectual property utilizes ...

(NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set to transform therapeutic development. By combining advanced artificial ...

ImaginAb, Inc., announces that it has entered into an agreement to sell a pipeline of next-generation therapeutic candidates, ...